ANI Pharmaceuticals (ANIP) CFO Stephen Carey Sells $240K of Stock

Stephen Carey, the Senior Vice President and CFO of ANI Pharmaceuticals, Inc. (ANIP), sold 2,850 shares on June 29, 2026. The transaction was valued at approximately $239,742, with shares selling at an average price of $84.12. This sale was part of a planned transaction, reflecting his ongoing financial strategy.

Carey’s sale brings his total holdings to 21,150 shares, a decline in percentage terms, although the exact percentage change was not specified. This move comes shortly after another insider, Meredith Cook, sold 500 shares worth about $41,015 on June 12, 2026, also as part of a planned transaction. Insider trades like these can signal financial maneuvers that may reflect the company’s future direction.

While no other funds reported changes in their positions, ANI Pharmaceuticals operates in a competitive landscape. The company develops and markets both branded and generic pharmaceutical products, serving various healthcare providers and pharmacies across the United States and internationally. Currently, ANI has no peers reporting activity in the latest filings, indicating a possible focus on internal management strategies.

At the recent closing price of $83.76, ANI's shares are trading significantly above the 52-week low of $69.58, suggesting a recent upward trend in the stock price. With a market cap of $1.81 billion, the company’s performance is closely watched, particularly as analysts maintain elevated price targets. The average target price stands at about $108.38, while analysts have issued a consensus recommendation of 'buy.'

On September 23, 2026, Oppenheimer initiated coverage with a 'Perform' rating and a target of $85. Guggenheim maintained a 'Buy' rating on August 10, lowering its target from $124.0 to $119.0, which still reflects confidence in the company's growth potential. In addition, Canaccord Genuity has various ratings, including a recent 'Hold' rating with a target of $90.0.

ANI Pharmaceuticals is known for its broad range of products including injectables, softgel capsules, and other pharmaceuticals. The company’s strategic moves in the market are indicative of its goals to enhance its portfolio and respond to changing healthcare needs.

Looking ahead, investors will be watching for ANI's next earnings report scheduled for November 6, 2026. This will provide further insight into the company's financial health and market position. As the 13F filings only reflect past holdings, ongoing insider trades and analyst ratings will be key indicators to monitor as the company progresses.